Alector says phase 1 study of al003 demonstrated a dose dependent and long-lasting target engagement in healthy volunteers

Alector showcases progress in immuno-neurology clinical programs and research portfolio at research and development day.alector inc - phase 1 study of al003 demonstrated a dose dependent and long-lasting target engagement in healthy volunteers.alector - phase 1 study of al002 demonstrated target engagement and indicated proof-of-mechanism in healthy volunteers.alector inc - results from phase 1b study of al001 in patients with symptomatic ftd-grn showing a statistically significant normalization.alector inc - plans to advance al001 into a phase 3 study in ftd-grn patients in 2020.
ALEC Ratings Summary
ALEC Quant Ranking